Biotech Analysis

Oxford BioMedica Loses TroVax Partner but Gets New Sanofi Deal
Oxford BioMedica plc has to start shopping around for a new partner for its TroVax therapeutic cancer vaccine after Paris-based Sanofi-Aventis dropped the late-stage program as part of a sweeping pipeline makeover. But the good news is that the Oxford, UK-based firm signed a new [...]

As of April 2009 and ordered by market capitalization:

Stock Ticker
Company Short Name
Market Capitalization
Stock Px
P/E Ratio
1Y Return
12M Revenue
12M EPS

AMGN US Equity
AMGEN INC
48,297,631,744
47.29
10.57
-18%
15,003,000,064
3.91

GILD US Equity
GILEAD SCIENCES
40,719,671,296
44.70
21.29
-13%
5,335,749,888
2.18

CELG US Equity
CELGENE CORP
18,732,310,528
40.77
29.76
-26%
2,254,780,992
-3.74

GENZ US Equity
GENZYME CORP
15,532,229,632
57.24
17.45
-14%
4,605,039,232
1.56

BIIB US Equity
BIOGEN IDEC INC
15,516,600,320
52.20
14.84
10%
4,097,506,880
2.68

ATLN VX Equity
ACTELION LTD-REG
5,756,683,776
46.13
19.21
-12%
1,362,169,817
2.52

LIFE US Equity
LIFE TECHNOLOGIE
5,676,325,888
32.66
11.40
40%
1,620,322,944
0.61

LONN VX Equity
LONZA GROUP -REG
4,988,434,944
98.88
12.71
15%
2,720,906,492
8.23

NZYMB DC Equity
NOVOZYMES-B SHS
4,560,102,912
70.16
22.57
-6%
1,607,726,917
3.40

ILMN US Equity
ILLUMINA INC
4,418,131,968
36.49
56.44
40%
573,225,016
0.44

VRTX US Equity
VERTEX PHARM
4,313,058,816
28.34
N.A.
-7%
175,504,000
-3.27

MYGN US Equity
MYRIAD [...]